RajD.S., ChoudhuryD., WelbourneT.C., LeviM.Advanced glycation end products: a nephrologist's perspective.Am J Kidney Dis2000; 35: 365–80.
2.
FriedmanE.A.Advanced glycation end products in diabetic nephropathy.Nephrol Dial Transplant1999; 14(Suppl 3): 1–9.
3.
LapollaA., FlaminiR., LupoA., AricòN.C., RugiuC., ReitanoR.Evaluation of glyoxal and methylglyoxal levels in uremic patients under peritoneal dialysis.Ann n y Acad Sci2005; 1043: 217–24.
4.
BrownleeM.Biochemistry and molecular cell biology of diabetic complications.Nature2001; 414: 813–20.
AgalouS., AhamedN., Babaei-JadidiR., DawnayA., ThornalleyP.J.Profound mishandling of protein glycation degradation products in uremia and dialysis.J Am Soc Nephrol2005; 16: 1471–85.
7.
MiyataT., van Ypersele de StrihouC., UedaY., IchimoriK., InagiR., OnogiH.Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms.J Am Soc Nephrol2002; 13: 2478–87.
8.
AgarwalR., CampbellR.C., WarnockD.G.Oxidative stress in hypertension and chronic kidney disease: role of angiotensin II.Semin Nephrol2004; 24: 101–14.
9.
OnozatoM.L., TojoA., GotoA., FujitaT., WilcoxC.S.Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB.Kidney Int2002; 61: 186–94.
10.
LewisE.J., HunsickerL.G., BainR.P., RohdeR.D.The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.N Engl J Med1993; 329: 1456–62.
11.
The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy.Lancet1997; 349(9069): 1857–63.
12.
LiP.K., ChowK.M., WongT.Y., LeungC.B., SzetoC.C.Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study.Ann Intern Med2003; 139: 105–12.
13.
SuzukiH., KannoY., SugaharaS., OkadaH., NakamotoH.Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD.Am J Kidney Dis2004; 43: 1056–64.
14.
KolesnykI., NoordzijM., DekkerF.W., BoeschottenE.W., KredietR.T.A positive effect of AII inhibitors on peritoneal membrane function in long-term PD patients.Nephrol Dial Transplant2009; 24: 272–7.
15.
FangW., OreopoulosD.G., BargmanJ.M.Use of ACE inhibitors or angiotensin receptor blockers and survival in patients on peritoneal dialysis.Nephrol Dial Transplant2008; 23: 3704–10.
16.
StrutzF., MullerG.A.Transdifferentiation comes of age.Nephrol Dial Transplant2000; 15: 1729–31.
17.
MiyataT., UedaY., Asahi, IzuharaY., InagiR., SaitoA.Mechanism of the inhibitory effect of OPB-9195 [(+/-)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-ylacetanilide] on advanced glycation end product and advanced lipoxidation end product formation.J Am Soc Nephrol2000; 11: 1719–25.
18.
MiyataT., UedaY., Yamada, IzuharaY., WadaT., JadoulM.Accumulation of carbonyls accelerates the formation of pentosidine, an advanced glycation end product: carbonyl stress in uremia.J Am Soc Nephrol1998; 9: 2349–56.
